Coya Therapeutics

COYA

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Coya Therapeutics is a small biotech company that is trying to develop new medicines for serious brain diseases. Its main focus is on conditions like ALS (Lou Gehrig's disease), Alzheimer's disease, and Parkinson's disease. The company is working on treatments that use the body's own immune system — specifically a type of cell called regulatory T cells — to slow or stop the damage these diseases cause.

Coya does not yet sell any approved products, so it currently earns almost no revenue. It spends money on clinical trials and research, which is why its operating margin is deeply negative. The company is based in Houston, Texas, and operates primarily in the United States. Its main competitive angle is its focus on regulatory T cell biology, which is a relatively specialized area of research. The biggest risk Coya faces is that its drug candidates could fail in clinical trials, which would leave it without a path to revenue and dependent on raising more cash to survive.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+49.0% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+22.2% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

3.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~9 months

$43.2B cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Strong grower

Coya Therapeutics is growing revenue at 49% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-2891.1%

Losing money on operations — -2891.1%

Return on the money invested

ROCE

-0.1%

Weak — -0.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

>+1,000%

Fast-growing sales (>+1,000% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-170635.6%

Burning cash (-170635.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial